Ranbaxy launches first biosimilar infliximab in India

December 1, 2014 9:47 AM

Ranbaxy Laboratories Limited (Ranbaxy), one of India’s largest pharmaceutical company, today announced the launch of Infimab (BOW015), the first Remicade (infliximab) biosimilar in India.

The product was launched at the Indian Rheumatology Association Conference (IRACON) in Chandigarh, in the presence of over a thousand rheumatologists and doctors from around the country.

Infimab, is being introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, Inc. a US and Swiss-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai. The innovator reference product is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.

Infimab marks Ranbaxy’s entry into mAb (Monoclonal Antibodies) biologics, and will help the company provide greater access to quality biologic medicines in management of conditions like rheumatoid arthritis.

Talking about the significance of the newly launched Infimab, Rajeev Sibal, Vice President & Country Head-India Region, Ranbaxy, said, “Infimab offers a new opportunity in the management of conditions like rheumatoid arthritis. The product has been developed as per global standards and delivers a similar clinical outcome to the innovator. It will be available in India at a very significant discount as compared to the innovator drug. More Indian patients will get the benefit of a world-class biologic treatment.”

Rheumatoid arthritis is one of the most common chronic inflammatory diseases that cause disability. The literature estimates a prevalence of 0.5% to 0.75% in India. To manage the disease, Indian rheumatologists are using Infliximab to treat only a select set of patients because it is very expensive.

Dr. Arvind Chopra, Consultant Rheumatologist, Pune who was also the Principal Investigator of Clinical Trial conducted in India with Infimab (BOW015), stated, “There has been an inordinate interest among the medical fraternity in India regarding the launch of Infimab as it is an affordable therapeutic alternative to Infliximab with equivalent clinical effectiveness. The availability of the new drug has widened our options to treat several forms of arthritis. This will increase patient access and many more Indian patients will benefit from this biologic treatment. The drug will not only be able to stop progression of rheumatoid arthritis but effectively control several of its complications that include bone damage, deformities and osteoporosis. Infimab also has an excellent treatment potential to treat other crippling painful arthritis like ankylosing spondylitis and psoriatic arthritis”.

Amit Munshi, president and CEO of Epirus, stated, “We are delighted to partner with Ranbaxy to bring Infimab to India. Infimab represents an affordable solution for patients and may expand patient access to this important medicine”.

It is well established through studies that if a biologic treatment is started relatively early and patients adhere for the required duration as recommended by the physician, significant improvement in overall treatment outcome can be achieved. Along with the affordable pricing of Infimab, Ranbaxy has launched RAISE (Rheumatoid Ailment Infimab Support Endeavor) a patient support program for improving patient awareness and compliance on therapy. With a similar clinical safety and efficacy to Remicade, a reduced cost of therapy, and patient support program, Infimab may encourage more patients to initiate and continue treatment, thus potentially improving the overall treatment outcome.


Source: Ranbaxy press release

1 Comment

  • vithalrao kulkarni malkhed

    Dear sir,it is great news to all Indians as only Remicade running in market it’s price is very very high..by make in India mission new govt has given approval for Infimab..please Ranbaxy has to declare the price soon..and when it available in Market..we all very curious to know..
    thanks to Ranbaxy,Relience Life science and Epirus..

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!